Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer
| Autor: | Winnie Janssens, Jan Dolhain, Frederik Fierens, Narcisa Mesaros, Linda Hanssens |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Drug Industry Vaccination schedule 030106 microbiology Immunology Primary vaccination Interchangeability Combination vaccines 03 medical and health sciences Immunogenicity Vaccine 0302 clinical medicine Antigen Drug Discovery Humans Medicine Hepatitis B Vaccines Vaccines Combined 030212 general & internal medicine Diphtheria-Tetanus-Pertussis Vaccine Immunization Schedule Haemophilus Vaccines Pharmacology business.industry Vaccination Dtpa hbv ipv hib Infant Virology Poliovirus Vaccine Inactivated Infanrix hexa Immunization Molecular Medicine business |
| Zdroj: | Expert Review of Vaccines. 17:513-524 |
| ISSN: | 1744-8395 1476-0584 |
| DOI: | 10.1080/14760584.2018.1419070 |
| Popis: | Combination vaccines improve vaccine uptake and open the infant immunization space for additional vaccines. Hexavalent vaccines have been marketed since 2000. Infanrix hexa (combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine, DTPa-HBV-IPV/Hib, GSK) is longest on the market, providing 16 years post-marketing experience. Each DTPa-HBV-IPV/Hib vaccine component is licensed alone and/or in smaller combination vaccines. Programmatic considerations sometimes require an interchange between vaccines due to unavailability, program change or mixed schedules (when the number of required antigens differs across scheduled primary vaccination visits).Immunogenicity and safety data from 11 GSK-sponsored clinical trials support the interchangeability of DTPa-HBV-IPV/Hib within the same vaccines family, and use of DTPa-HBV-IPV/Hib in mixed primary vaccination schedules.Data show acceptability of interchange of DTPa-HBV-IPV/Hib with other products within the same vaccines family and its use in mixed immunization schedules. This aligns with WHO recommendations that vaccines of the same family from the same manufacturer be used to complete the infant vaccination schedule. Interchangeability and suitability for use in mixed schedules is of interest for policy-makers/providers in the framework of vaccination recommendations as it provides flexibility. Given the complexity of larger combination vaccines, interchangeability or sequential use needs careful assessment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|